Ÿnsect’sFailure: How Hype Overcame Reality in Insect Farming
The spectacle of a Hollywood star driving a startup to prominence is a familiar tale in tech. For French insect farming pioneer Ÿnsect, Robert Downey Jr.’s enthusiastic endorsement on The Late Show during Super Bowl weekend 2021 catapulted the company into global headlines. Yet, just four years later, Ÿnsect has been placed into judicial liquidation – effectively declaring bankruptcy – after raising over $600 million from investors including Downey Jr.’s Footprint Coalition, public investment bank Bpifrance, and impact-focused firms like Astanor Ventures. This dramatic fall raises critical questions about ambition, execution, and the harsh realities of scaling deep tech.
The company’s downfall wasn’t primarily about overcoming Western squeamishness towards edible insects. As Professor Joe Haslam, scaling expert at IE Business School, notes, “Ÿnsect’s struggles are not a mystery and not mainly about insects.” Human food, while a visionary goal, was never its core focus. Instead, Ÿnsect pinned its hopes on producing insect protein for animal feed and pet food – two markets with fundamentally different economics. The critical error? A dangerous indecision. While acquiring Dutch mealworm specialist Protifarm in 2021 aimed to enter human food, CEO Antoine Hubert openly admitted its human food revenue would take years to reach just 10-15% of total sales. The company doubled down on pet food and fish feed, acknowledging their higher margins and demand, yet simultaneously poured resources into Ÿnfarm, its ambitious “world’s most expensive bug farm” giga-factory in Northern France.
This misalignment proved catastrophic. Revenue from Ÿnsect’s main entity peaked at a reported €17.8 million in 2021 – figures likely inflated by internal transfers. By 2023, the company faced a staggering net loss of €79.7 million. The giga-factory, requiring hundreds of millions in funding before proving its viability or unit economics, became an anchor. The 2023 pivot to pet food, recognizing it as a better-margin market, arrived too late. By then, the company was already committed to a massive, capital-intensive bet built on flawed assumptions about the animal feed market – a commodity driven by price, not sustainability premiums. Insect protein, often reliant on existing cereal by-products instead of truly circular waste streams, simply didn’t offer the cost advantage needed. The vision collided hard with market reality.
Ÿnsect’s failure serves as a stark case study in what Professor Haslam identifies as a broader European scaling gap. “We fund moonshots. We underfund factories. We celebrate pilots. We abandon industrialization,” he observes. Successes like Northvolt (battery tech) and failures like Volocopter and Lilium highlight the systemic challenge. The collapse underscores the necessity beyond just capital: robust industrial strategy, realistic market timing, and the discipline to stick to the most profitable path rather than chasing peripheral opportunities. As Ÿnsect’s former CEO and last CEO acknowledged, its accumulated expertise and relationships will hopefully find new purpose. For the insect farming sector as a whole, the lessons from Ÿnsect’s implosion – prioritizing proven profitability over speculative diversification and ensuring capital expenditure aligns with validated business models – are invaluable. The ambition to revolutionize protein supply chains remains valid; the path forward demands a sharper focus on execution and market realities.
No Comments